drugset / Trial / NCT02750748

Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers

NCT02750748

Phase 1 Completed 14 enrolled National Institute on Drug Abuse (NIDA)
RandomizedCrossoverOpen-labelTreatment

Summary

To determine the pharmacokinetics of 2 intranasal doses and 1 oral dose of naltrexone compared to an intramuscular dose of naltrexone.

Timeline

Start
2016-07
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Naltrexone Small molecule 2 mg Intranasal
Subject Naltrexone Small molecule 4 mg Intranasal
Subject Naltrexone Small molecule 50 mg Intranasal